Descripción del proyecto
Una plataforma de cáncer en un chip para el descubrimiento de fármacos
Los cultivos celulares tridimensionales se están posicionando como modelos prometedores para el descubrimiento de fármacos antineoplásicos, la toxicología y los estudios preclínicos y de medicina personalizada. Estos cultivos no solo poseen una naturaleza biomimética y favorecen la reproducibilidad de los resultados, sino que además facilitan la reducción de la experimentación animal. El proyecto financiado con fondos europeos MImETIC INDiRECT ha desarrollado un sistema de cultivo microfluídico que incluye una cámara de chip recubierta con una matriz extracelular, así como sensores de temperatura y oxígeno. Es más, este sistema emplea medios de cultivo optimizado con factores de crecimiento y es compatible con equipos de imagenología. Los investigadores del proyecto emplearán líneas celulares para reconstruir modelos de cáncer tridimensionales «in vitro» y promoverán estas plataformas versátiles de células en un chip para su comercialización.
Objetivo
MImETIC INDiRECT aims to develop a standardised, accessible, versatile organ-on-chip toolkit for cancer biology and drug discovery research, compatible with microscopy-based (live imaging and confocal) techniques. The project is expected to facilitate academia and industry adoption of microfluidic 3D cell culture systems for comparable and reproducible results in a complex biomimetic animal free model for cancer drug discovery, toxicology, advanced (pre)clinical as well as personalized medicine. The toolkit components will consist of an integrated temperature controller dual-chamber chip, the Cherry Biotech CubiX system and growth factor optimized collagenous solutions for each chip chamber. The dual chamber chip, with cellular migration lanes, will have two tailored collagen-based formulations, designed per chamber. The CubiX platform is a compact flow and temperature controller, allowing optional sensor (e.g. O2) integration, compatible with single chips or 24-well plates. The cancer(s) sub-types to be used toolkit standardization will be dictated by market needs, where commercial cell lines (cancerous and non-cancerous) will be used to create the microvascularized complex tissue model. Potential project risks have been identified with appropriate mitigation strategies, where the project promotes adoption of standardized, cost-effective and versatile cancer organ-on-chip platforms in the market, rather than disruptive academic findings. Access of the aforementioned system to a worldwide growth market will fully exploit the project results, disseminated by direct and indirect marketing and scientific approaches. Project implementation will be an academic-industry collaborative and multidisciplinary manner providing the acquisition of diverse and unconventional complementary skills, leading to an understanding of both sectors requirements. We envision the above-mentioned to facilitate future academic and industry collaborations.
Ámbito científico
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- engineering and technologyelectrical engineering, electronic engineering, information engineeringelectronic engineeringsensors
- medical and health sciencesclinical medicineoncology
- medical and health scienceshealth sciencespersonalized medicine
- engineering and technologyother engineering and technologiesmicrotechnologyorgan on a chip
Programa(s)
Régimen de financiación
MSCA-IF-EF-SE - Society and Enterprise panelCoordinador
93100 Montreuil
Francia
Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención.